Q-omics provides the consensus-scored ZNF665 profile across patient tissues and cancer cell-line models. ZNF665 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF665 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, ZNF665 RNA expression shows 20,225 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, HNSC, and THYM as cancer lineages where ZNF665 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF665 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF665 survival associations across molecular data types. ZNF665 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF665 RNA expression–survival associations across cancer types. High ZNF665 expression shows unfavorable associations in LUSC and LGG, but favorable associations in UVM, UCS, LUAD and STAD. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF665 RNA expression.
This table summarizes ZNF665 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF665. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF665 shows lower tumor expression in HNSC, THCA, UCEC and LUSC and higher tumor expression in LIHC and CHOL. The HNSC box plot shows higher ZNF665 RNA expression in normal versus tumor tissue (log2 FC = −0.197, t-test p = .001).
This table shows molecular features associated with ZNF665 in patient tissues and cancer cell lines. In patient samples, ZNF665 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF665 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
